Ratio Therapeutics Funding Round

1/17/2024

Venture Equity

$50,000,000

Series B

Additionally, the funding will drive the clinical development of the company's fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic.

Private & Independent

Biopharmaceutical

77 Sleeper St
Boston, MA 02210
USA

Undisclosed

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics' Trillium� targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.